BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Life Medical Sciences (CHAI) Launches Drug Delivery Development Program


10/19/2005 5:11:16 PM

OCEANPORT, N.J., May 12 /PRNewswire-FirstCall/ -- During a presentation today at the Rodman & Renshaw TechVest Global Healthcare Conference in London, Robert P. Hickey, President & CEO of Life Medical Sciences, Inc. (BULLETIN BOARD: CHAI) , will announce that the Company has undertaken a development program intended to provide cardiac surgeons with the first ever localized drug delivery product intended to prevent the onset of surgically-induced atrial fibrillation.

Approximately one third of patients undergoing open heart surgery develop atrial fibrillation, or irregular heart beat, resulting from the trauma of the surgical procedure. This complication is currently treated with systemic drug delivery and requires increased patient monitoring and results in delayed discharge from the hospital. Similar to drug eluding stents, the drug would be impregnated into the Company's REPEL-CV bioresorbable film which is designed to be placed on the surface of the heart during the surgical procedure. The objective is to deliver the drug to the heart tissue as the film resorbs, thus eliminating the need for expensive systemic drug delivery.

Mr. Hickey will also state that patient enrollment in the multi-center, pivotal clinical trial for REPEL-CV bioresorbable adhesion barrier in cardiac surgery is proceeding on schedule with a targeted completion date for the trial still anticipated in mid-2005.

Life Medical Sciences, Inc. is a biomaterials company engaged in the development and commercialization of innovative and cost-effective medical devices. The Company is developing a broad range of bioresorbable polymer products to prevent/reduce post-operative adhesion formation.

Certain statements in this Press Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2003 for a description of some of these risks and uncertainties.

Life Medical Sciences, Inc.

CONTACT: Robert P. Hickey of Life Medical Sciences, Inc.,+1-732-728-1769, rphickey@lifemedicalsciences.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES